Clinical Experiences with Aclacinomycin-A

  • H. Furue
  • T. Komita
  • I. Nakao
  • I. Furukawa
  • T. Kanko
  • T. Yokoyama
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 63)

Abstract

Aclacinomycin A (subsequently referred to as ACM) is a new anticancer agent of the anthracycline group, and was isolated and purified by Dr. Hamao Umezawa in 1974 from a culture of Streptomyces galilaeus. With a chemical structure as shown in Fig. 1, ACM is similar in basic structure to adriamycin (ADM) and daunomycin (DNM), but differs from the latter in that it contains three sugars, rhodosamine, 2-deoxyfueose and L-cinerulose. Basic studies of this compound have revealed the following characteristics of the agent:
  1. 1.

    ACM may be classified among the drugs of the anthracycline group such as DNM and ADM.

     
  2. 2.

    The LD50s of ACM in mice, rats and hamsters by any route of administration are 2–3 times as high as those of DNM and of ADM (Table 1).

     
  3. 3.

    ACM differs slightly in anticancer spectrum from DNM and ADM.

     
  4. 4.

    4. ACM is taken up by the lungs at high concentrations, and also by the spleen.

     
  5. 5.

    Both acute and subacute cardiotoxicity of ACM measured in terms of ECG patterns.

     

Keywords

Cholesterol Sugar Hydrolysis Toxicity Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • H. Furue
  • T. Komita
  • I. Nakao
  • I. Furukawa
  • T. Kanko
  • T. Yokoyama

There are no affiliations available

Personalised recommendations